Immunovia AB (SE:IMMNOV)
:IMMNOV
Want to see SE:IMMNOV full AI Analyst Report?
IMMNOV Stock Chart & Stats
kr0.23
-kr0.02(-4.98%)
At close: 4:00 PM EST
kr0.23
-kr0.02(-4.98%)
Day’s Range― - ―
52-Week Rangekr0.15 - kr0.75
Previous CloseN/A
Volume868.16K
Average Volume (3M)5.10M
Market Cap
kr137.22M
Enterprise Valuekr13.23M
Total Cash (Recent Filing)kr56.09M
Total Debt (Recent Filing)kr479.00K
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Aug 06, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding672,666,900
10 Day Avg. Volume6,199,351
30 Day Avg. Volume5,096,607
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)114.10
P/FCF Ratio-1.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)kr4.40M
Bulls Say, Bears Say
Bulls Say
Medicare Pricing & Billing CodeEstablishing a Medicare reimbursement rate and billing code is a durable commercial milestone. It creates a standardized billing path that supports payer negotiations and future claim payments, increasing the likelihood of predictable per-test reimbursement and enabling scalable revenue once formal coverage is granted.
Strong Clinical ValidationMultiple peer‑reviewed studies and conference podiums provide sustained scientific credibility. Robust clinical evidence reduces adoption risk among specialty centers, strengthens reimbursement submissions, and supports long-term clinician trust and guideline inclusion—key structural drivers for diagnostic test uptake.
Very Low Financial LeverageMinimal debt materially lowers refinancing and interest-rate pressure, preserving financial flexibility. Low leverage gives the company room to prioritize commercial rollout and clinical studies without near-term interest obligations, reducing solvency risk relative to highly leveraged peers.
Bears Say
Persistent Cash BurnSustained negative free cash flow at scale creates structural funding exposure: management notes runway only through Q3 2026 without new capital. Ongoing cash burn forces dilutive fundraising or partnership dependence, constraining independent commercialization and long-term strategic optionality.
Negative Gross Profit & MarginsRecurring negative gross profit signals the core business has not reached unit-level economics that support sustainable scaling. Even with cost discipline, negative margins imply the model currently destroys value at volume, raising structural questions about pricing, cost base, or test economics until materially improved.
Payer Coverage UncertaintyBilling code and price do not equal reimbursed revenue: absent formal payer coverage, collection timing and realized per-test payments are uncertain. This structural coverage gap can materially delay revenue recognition, depress cash collections, and amplify financing needs during the commercial ramp.
Immunovia AB News
IMMNOV FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was kr0.15 and its highest was kr0.75 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is kr137.22M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on May 07, 2026. The company reported -kr0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.03.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is -0.04.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -kr0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 17.143%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in SE:IMMNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
IMMNOV Company Deck
IMMNOV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful commercial, scientific and reimbursement progress: a successful product launch, strong clinical publications and podium presence, an awarded Medicare pricing of USD 897, state approvals in 48 states, targeted hiring of account managers, and a completed rights issue that improved cash position. However, near-term revenue remains limited, full payer coverage is not yet granted, cash runway extends only to Q3 2026 without additional capital, and realized per-test pricing and collections are still uncertain. The company emphasized disciplined spending, planned clinical utility data collection (including a 400-patient registry) and a mid-2026 Medicare submission with rolling data updates to mitigate coverage risk.View all SE:IMMNOV earnings summariesTechnical Analysis
Alligator Bioscience AB
―
Prostatype Genomics AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Klaria Pharma Holding AB
―